Supernus pharmaceuticals to participate in the td cowen 4th annual novel mechanisms in neuropsychiatry summit

Rockville, md., sept. 19, 2024 (globe newswire) -- supernus pharmaceuticals, inc. (nasdaq: supn), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) diseases, announced today that jack khattar, president and ceo of supernus pharmaceuticals, will participate virtually in a fireside chat at the td cowen 4th annual novel mechanisms in neuropsychiatry summit on thursday, september 26, 2024, at 8:40 a.m. et.
COWN Ratings Summary
COWN Quant Ranking